After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Macrogenics Inc is $1.01B. A total of 0.59 million shares were traded on the day, compared to an average of 1.59M shares.
In the most recent transaction, Peters Jeffrey Stuart sold 51,395 shares of MGNX for 15.55 per share on Apr 04 ’24. After the transaction, the Senior VP and General Counsel now owns 0 company shares. In a previous transaction on Mar 06 ’24, Peters Jeffrey Stuart sold 19,625 shares at 21.50 per share. MGNX shares that Senior VP and General Counsel owns now total 8,895.
Among the insiders who sold shares, Risser Eric Blasius disposed of 41,159 shares on Mar 04 ’24 at a per-share price of $19.76. This resulted in the Chief Operating Officer holding 38,900 shares of MGNX after the transaction. In another insider transaction, Karrels James sold 30,000 shares at $20.50 per share on Mar 04 ’24. Company shares held by the SVP, CFO and Secretary now total 171,452.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, MGNX has a high of $21.88 and a low of $4.29.
As of this writing, MGNX has an earnings estimate of $Cognex Corporation per share for the current quarter. EPS was calculated based on a consensus of Magnite, Inc. estimates, with a high estimate of $MacroGenics, Inc. per share and a lower estimate of $REGENXBIO Inc..
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. MGNX’s latest balance sheet shows that the firm has $243.62M in Cash & Short Term Investments as of fiscal 2021. There were $25.47M in debt and $74.58M in liabilities at the time. Its Book Value Per Share was $2.46, while its Total Shareholder’s Equity was $239.62M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MGNX is Buy with a score of 4.80.
